Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
NCT ID: NCT03775525
Last Updated: 2022-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
127 participants
INTERVENTIONAL
2019-03-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of GZ17-6.02 monotherapy and in combination with standard-of-care oncology treatments and to establish the dose of GZ17-6.02 recommended for future monotherapy and combination therapies phase II oncology clinical studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: monotherapy
GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.
GZ17-6.02
Super enhancer Inhibition
Experimental: Combination with Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
GZ17-6.02 given orally twice daily x 21 day schedule in combination with Capecitabine 825 mg/m2 orally twice daily for 14 days x 21 day schedule.
GZ17-6.02
Super enhancer Inhibition
Capecitabine
antimetabolite
Experimental: Combination with Capecitabine in Metastatic Colorectal Cancer
GZ17-6.02 given orally twice daily x 21 day schedule in combination with Capecitabine 850 mg/m2 orally twice daily for 14 days x 21 day schedule.
GZ17-6.02
Super enhancer Inhibition
Capecitabine
antimetabolite
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GZ17-6.02
Super enhancer Inhibition
Capecitabine
antimetabolite
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tumor progression after receiving standard/approved therapies which may include chemotherapy, targeted agents, radio-immuno conjugates, check point inhibitors, where there is no approved therapy; or the patient is intolerant of standard of care or the patient declines standard of care treatment
* One or more metastatic tumors measurable, or evaluable, per RECIST v1.1 Criteria for solid tumors and Lugano Criteria for lymphoma
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
* Life expectancy of at least 3 months
* Age 18 years
* Signed, written IRB-approved informed consent
* A negative pregnancy test (if female)
* Acceptable liver function:
* Bilirubin ≤ 1.5 times upper limit of normal
* AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2.5 times upper limit of normal (if liver metastases are present, then ≤ 5 x ULN is allowed)
* Acceptable renal function:
o Serum creatinine ≤ 1.5 times institutional ULN, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
* Acceptable hematologic status:
* Granulocyte ≥ 1500 cells/mm3
* Platelet count ≥ 100,000 (plt/mm3)
* Hemoglobin ≥ 9 g/dL
* Urinalysis:
o No clinically significant abnormalities
* Acceptable coagulation status (for patients on warfarin or other anti-coagulants, a PT/PTT considered by the PI as therapeutically appropriate will be allowed):
* PT within ≤ 1.5 times normal limits
* PTT within ≤ 1.5 times normal limits
* For men and women of child-producing potential, the use of effective contraceptive methods during the study
* Fasting glucose ≤ 180 mg/dL
* Albumin ≥ 3.0 g/dL within seven days of initiating protocol treatment
For patients in the GZ17-6.02 plus capecitabine Phase 1b Expansion Cohort 2 (metastatic breast cancer):
* Pathologically confirmed diagnosis of HER2-negative and Hormone Receptor (HR) (estrogen receptor \[ER\] and/or progesterone receptor)-positive metastatic breast cancer;
* Had ≤ 1 prior treatment (not including neoadjuvant or adjuvant treatment);
* Are naïve to capecitabine but not necessarily to fluorouracil (5 FU);
* Eligible for standard-of-care treatment with capecitabine monotherapy.
* Patients in Expansion Cohort 2 with bone-only metastatic disease must have one or more lytic or a mixed lytic-blastic lesions that can be assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI).
For patients in GZ17-6.02 plus capecitabine Phase 1b Expansion Cohort 3 (metastatic colorectal cancer):
* Pathologically confirmed diagnosis of metastatic colorectal cancer;
* Had ≤ 2 prior treatments (not including neoadjuvant or adjuvant treatment);
* Are naïve to capecitabine but not necessarily to 5 FU;
* Eligible for standard-of-care treatment with capecitabine monotherapy.
Exclusion Criteria
* Currently taking MAOIs
* Baseline QTc exceeding 450 msec in males, 470 msec in females (using the Fridericia's formula) and/or patients receiving class 1A or class III antiarrhythmic agents;
* Known active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy;
* Pregnant or nursing women.
* NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* Treatment with radiation therapy or surgery within 1 month prior to study entry.
* Treatment with chemotherapy, targeted therapeutics (e.g. tyrosine kinase inhibitors, therapeutic antibodies, etc), or investigational therapies within 1 month, or 5 half-lives (whichever is shorter), prior to study entry (6 weeks for nitrosoureas or mitomycin C). For radiopharmaceuticals, within 1 month unless hematopoietic recovery has not returned to pretreatment baseline;
* Unwillingness or inability to comply with procedures required in this protocol;
* Known active infection with HIV, HTLV-1, hepatitis B, hepatitis C or other chronic viral infections that could interfere with the interpretation of study data;
* Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.
* Patients who are currently receiving any other investigational agent;
* Primary Central Nervous System (CNS) malignancies;
* Active CNS metastases requiring treatment or radiotherapy, or which have not been confirmed stable on radiographic imaging for ≥30 days prior to C1D1;
* Patients requiring steroids for neurological signs and symptom stabilization.
* Patients who are unable to successfully discontinue all prohibited medications listed in Appendix 6;
* Patients must not have received a transfusion (platelets or red blood cells) ≤ 2 weeks prior to initiating protocol therapy.
For patients in the GZ17-6.02 monotherapy Dose Escalation Cohort and patients in Expansion Cohort 1:
• Patients with cow's milk allergy or with galactosemia
Phase 1b Expansion Cohort 2 (metastatic breast cancer) and Expansion Cohort 3 (metastatic colorectal cancer):
* Any history of coronary artery disease is exclusionary; New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on the ECG.
* Any conditions or medications that are contraindicated with capecitabine dosing;
* Dihydropyrimidine dehydrogenase (DPD) deficiency;
* Known sensitivity to capecitabine or any of its components or to 5-FU ;
* Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
o This includes prior gastrointestinal surgery that would interfere with the oral drug absorption.
* Malignancy other than metastatic breast cancer (Expansion Cohort 2) or metastatic colorectal cancer (Expansion Cohort 3) that required therapy within the preceding 5 years, other than adequately treated:
* non-melanoma skin cancer or in situ cancer;
* another cancer that has a very low risk of interfering with the safety or efficacy endpoints of the study, must be approved by the Sponsor medical team.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Translational Drug Development
OTHER
Genzada Pharmaceuticals USA, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathryn Gazarik
Role: STUDY_DIRECTOR
Translational Drug Development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HonorHealth Research Institute
Scottsdale, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Booth L, West C, Von Hoff D, Dent P. Mechanisms of GZ17-6.02 resistance. Anticancer Drugs. 2022 Jun 1;33(5):415-423. doi: 10.1097/CAD.0000000000001203.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GEN-602-CT-101
Identifier Type: -
Identifier Source: org_study_id